FLOT vs. FLOT/Herceptin/Pertuzumab for Perioperative Therapy of HER-2 Expressing Gastric or GEJ Cancer
Status:
Completed
Trial end date:
2020-07-17
Target enrollment:
Participant gender:
Summary
Previous studies provide a strong theoretical rationale for the conduct of a randomized study
evaluating the efficacy and safety of Herceptin and pertuzumab in combination with FLOT in
the perioperative treatment of resectable HER-2 positive adenocarcinoma of the stomach or
GEJ.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest Krankenhaus Nordwest